Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREVI-OC-02 maintenance study of torvutatug samrotecan plus bevacizumab versus bevacizumab alone in HRD-negative advanced ovarian cancer
jRCT2051260207Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Torvutatug samrotecan + Bevacizumab with Bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Oct 2026; status: recruiting.
02
Drugs
torvutatug samrotecanbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2051260207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260207.